知镜 Cognispect · 医学文献与研究工作台

Prevalence of antimicrobial resistance in Campylobacter spp. and Salmonella spp. in Switzerland 2007-2022: a retrospective observational study.

Jung F, Vogt DR, Stephan R, Kronenberg A, Egli A, The Swiss Antibiotic Resistance Centre Anresis.
Swiss medical weekly · 2026-10-30 · PMID 43037560

文献摘要

Background In Switzerland, acute infectious diarrhoea is frequently caused by Campylobacter spp. and Salmonella spp. The rise of antimicrobial resistance complicates treatment and underscores requirements for continuous surveillance. We aimed to analyse the development of antimicrobial resistance in Campylobacter spp. and Salmonella spp. isolated from human samples in Switzerland over time. Methods We conducted a retrospective observational analysis using the ANRESIS database, covering the period from January 2007 to December 2022. The study included 47,498 Campylobacter spp. isolates and 5964 Salmonella enterica isolates. Antimicrobial resistance was categorised according to CLSI or EUCAST. Descriptive statistical analyses were performed to explore resistance over time, focusing on pathogens and invasive versus non-invasive isolates. Results The majority of Campylobacter isolates were Campylobacter jejuni (80.4%) and Campylobacter coli (7%). Resistance to ciprofloxacin in Campylobacter jejuni increased from 38% in 2007 to 81% in 2022. Resistance to doxycycline and tetracycline also rose sharply between 2012 and 2014, reaching approximately 37% by 2022. Resistance to macrolides remained consistently low ( Conclusions The increasing prevalence of antimicrobial resistance in Campylobacter spp. and Salmonella spp. in Switzerland emphasises the critical need for ongoing surveillance and judicious antibiotic use.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。